- Paolo Boffetta, epidemiologist,
- Kurt Straif, epidemiologist
- Correspondence to: P Boffetta, Genetics and Epidemiology Cluster, International Agency for Research on Cancer, 150 Cours Albert Thomas, 69008 Lyon, France boffetta{at}iarc.fr
- Accepted 30 March 2009
Abstract
Objective To assess whether people who use smokeless tobacco products are at increased risk of myocardial infarction and stroke.
Design Meta-analysis of observational studies from Sweden and the United States.
Data sources Electronic databases and reference lists.
Data extraction Quantitative estimates of the association between use of smokeless tobacco products and risk of myocardial infarction and stroke among never smokers.
Review methods Both authors independently abstracted risk estimates and study characteristics. Summary relative risks were estimated on the basis of random effects models.
Results 11 studies, mainly in men, were included. Eight risk estimates were available for fatal myocardial infarction: the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence 1.06 to 1.21) and the excess risk was restricted to current users. The relative risk of fatal stroke, on the basis of five risk estimates, was 1.40 (1.28 to 1.54). The studies from both the United States and Sweden showed an increased risk of death from myocardial infarction and stroke. The inclusion of non-fatal myocardial infarction and non-fatal stroke lowered the summary risk estimates. Data on dose-response were limited but did not suggest a strong relation between risk of dying from either disease and frequency or duration of use of smokeless tobacco products.
Conclusion An association was detected between use of smokeless tobacco products and risk of fatal myocardial infarction and stroke, which does not seem to be explained by chance.
Footnotes
We thank Sharon Grant, International Agency for Research on Cancer, for help with the literature search.
Contributors: Both authors had full access to all of the data in the study and are jointly responsible for the integrity of the data and the accuracy of the data analysis.
Funding: This study received no funding.
Competing interests: None declared.
Ethical approval: Not required.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: The comforts of spiritualism
Published 23 May 2012
Re: The hardest thing: admitting error
Published 23 May 2012
Ice cream headache as a new example of “Cold headache” in Avicenna’s manuscript
Published 23 May 2012
Re: Randomised controlled trial of homoeopathy versus placebo in perennial allergic rhinitis with overview of four trial seriesCommentary: Larger trials are needed
Published 23 May 2012
Re: Testing athletes, and banning those who take drugs, is unjustifiable
Published 23 May 2012
Most responses
The psychiatric oligarchs who medicalise normality (8 responses)
Published 2 May 2012
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21
The hardest thing: admitting error (7 responses)
Published 2 May 2012 - 12:27
Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10 (6 responses)
Published 10 May 2012 - 23:32